The deletion is interacting with multiple variants across an individual's genome.
Two children can inherit the same chromosomal deletion and live radically different lives—one burdened by severe intellectual disability, another navigating only mild anxiety—and for years, medicine could not explain why. A Penn State research team has now illuminated the answer: it is not the deletion alone that determines fate, but the entire genetic landscape surrounding it, a chorus of variants scattered across the genome that together shape what the deletion becomes. Published in Nature Communications, their work challenges the long-held instinct to seek a single causal mutation and replaces it with a more humbling truth—that genetic disease is often a conversation between many voices at once.
- The same 16p12.1 chromosomal deletion produces wildly different outcomes across patients, from profound developmental delay to manageable psychiatric symptoms, leaving families and clinicians without reliable predictions.
- Decades of research built around single-gene causation have failed to explain this variability, creating a diagnostic and therapeutic blind spot for thousands of affected individuals.
- Penn State researchers used iPSCs and CRISPR editing across multiple family cell lines to demonstrate that each family's unique genetic background reshapes how the deletion disrupts gene expression and cellular behavior.
- Restoring each of the eight deleted genes one at a time revealed that the deletion interacts with dozens of scattered genetic variants—not just one or two—collapsing the old 'two-hit' disease model entirely.
- Even healthy carriers were found to harbor genetic constellations that could amplify risk in their children, suggesting invisible inheritance pathways that current screening does not capture.
- The findings point toward a future of family-specific precision medicine, where treatment protocols are designed around an individual's full genomic architecture rather than a single shared diagnosis.
Two children inherit the same deletion on chromosome 16. One develops severe intellectual disability. The other grows up managing anxiety and depression. Same genetic flaw—radically different lives. For over a decade, that gap has haunted researchers.
A Penn State team led by Santhosh Girirajan has begun to close it, and their answer reshapes how we understand genetic disease. The deletion—a segment of chromosome 16 called 16p12.1—removes eight genes and has been linked to autism, developmental delay, and congenital abnormalities. But severity varies wildly between families. Rather than hunting for a single causal mutation, Girirajan's group asked a different question: how does a person's entire genetic landscape interact with the deletion to determine what actually unfolds?
The inheritance pattern offered an early clue. Most children with the deletion inherited it from a parent who carries it but shows few or no symptoms. When a child receives the deletion from one parent and the rest of their genome from the other, a new genetic context is created—one in which the same broken piece of machinery behaves differently depending on what surrounds it.
To test this, the team worked with two complementary methods. They derived induced pluripotent stem cells from patients, family members, and healthy controls, coaxing them into neurons and comparing gene expression across families. Some cell lines showed abnormal proliferation; others showed premature death or early differentiation. These problems differed family by family. They also used CRISPR to restore each of the eight deleted genes individually, finding that each restored gene affected a different set of downstream genes—and those sets shifted between families and cell types.
The old 'two-hit' model—one primary mutation, one secondary—could not survive this evidence. Graduate student Serena Noss describes the new picture: the deletion isn't hitting twice. It's hitting many times, in different combinations, depending on what other variants a person carries. Even more striking, when the team introduced the deletion into cells from a healthy donor, that person's genetic background still contained variants capable of contributing to neurodevelopmental problems in the deletion's presence—suggesting that seemingly healthy carriers may unknowingly pass on risk through their particular constellation of genes.
The implications reach directly into clinical practice. If outcomes depend on an individual's full genomic architecture, then treatment must be tailored to that architecture. A therapy suited to one family may fail another. For families carrying the 16p12.1 deletion, this research opens a path toward interventions built around their specific genetic context—a meaningful step away from one-size-fits-all medicine and toward something more precise, and more human.
Two children inherit the same deletion on chromosome 16 from their parents. One develops severe intellectual disability and profound developmental delay. The other grows up with manageable anxiety and depression. Same genetic flaw. Radically different lives. The question that has haunted researchers for over a decade is why.
A team at Penn State has begun to answer it, and the answer rewrites how we think about genetic disease. The deletion in question—a section of chromosome 16 called 16p12.1—removes eight genes and has been linked to autism, developmental delay, and various congenital abnormalities. But the severity and type of symptoms vary wildly from one family to the next. Santhosh Girirajan, who leads the research group, explains that the conventional approach to genetic disorders has been to hunt for a single causal mutation. This study moves in a different direction entirely: it asks how the entire genetic landscape of a person—all the variants they carry across their whole genome—interact with the deletion to shape what actually happens.
The inheritance pattern itself offers a clue. Most children with the 16p12.1 deletion inherited it from a parent who carries it but may show no symptoms at all. When a child inherits the deletion from one parent, they receive half their genetic material from the other parent—the one without the deletion. That new combination of genes creates a different context for the deletion to operate in. It's as though the same broken piece of machinery behaves differently depending on what other machinery surrounds it.
To test this hypothesis, the researchers used two complementary approaches. The first involved induced pluripotent stem cells—iPSCs—derived from blood samples of patients with the deletion, their family members, and healthy controls. These cells can be coaxed into becoming different types of neurons. By comparing how genes were expressed in neurons from different families, and by using CRISPR to introduce the deletion into cells from healthy donors, the team could observe what went wrong at the cellular level. Some cell lines showed abnormal cell proliferation, others showed premature cell death or early differentiation. Crucially, these problems differed from family to family. The researchers also sequenced the entire genome of each cell line and measured gene expression across all cell types. What emerged was a pattern: the genetic background unique to each family influenced which genes were turned up or down, and which regions of the genome were accessible for regulation.
The second strategy involved using CRISPR to restore, one at a time, each of the eight genes deleted in the 16p12.1 region. When they did this, each restored gene affected a different set of downstream genes—and those sets differed between families and between cell types. This finding shattered the old "two-hit" model, in which a disease was caused by one primary mutation plus one secondary mutation elsewhere. The deletion, it turned out, was interacting with multiple genetic variants scattered across the genome. Serena Noss, a graduate student on the team, describes the shift in thinking: the deletion isn't hitting twice. It's hitting many times, in different combinations, depending on what other genetic variants a person carries.
Even more striking: when the researchers introduced the deletion into cells from a completely healthy donor using CRISPR, they found that this healthy person's genetic background still contained variants that could contribute to neurodevelopmental problems in the presence of the deletion. This suggests that seemingly healthy carriers might pass on risk to their children without knowing it—not because they carry a disease, but because their particular constellation of genetic variants, when combined with the deletion, produces different outcomes.
The implications are substantial. If the severity and type of neurodevelopmental disorder caused by the 16p12.1 deletion depends on an individual's entire genetic architecture—not just one or two additional mutations—then treatment might need to be tailored to that architecture. A therapy that works for one family might not work for another. The research, published in Nature Communications, suggests that precision medicine for complex genetic disorders will require understanding not single genes but the intricate web of interactions across a person's genome. For families carrying the deletion, this opens a path toward interventions designed specifically for their genetic context rather than a one-size-fits-all approach.
Notable Quotes
We've moved away from the 'two-hit' model because we realize the deletion is interacting with multiple variants across an individual's genome. It's really more of a multi-hit model.— Serena Noss, graduate student, Penn State
A child that inherits the deletion from one parent gets half its genome from the other parent. This new combination of genetic information might expose the deletion to a different set of genetic variants that it can interact with to cause different features.— Santhosh Girirajan, Penn State
The Hearth Conversation Another angle on the story
Why does the same genetic deletion cause such different outcomes? Is it just bad luck?
Not luck—it's the rest of your genome. When you inherit the deletion from one parent, you inherit half your genes from the other parent. That creates a unique genetic context. The deletion behaves differently depending on what other variants are present.
So it's like the same broken part works differently in different machines?
Exactly. And the machines aren't just slightly different. Each family has its own set of rare genetic variants that interact with the deletion in specific ways. We found those interactions are family-specific.
How did you actually see this happening?
We grew neurons from patients' cells and from healthy people. Then we used CRISPR to introduce the deletion into healthy cells. We could watch the cells behave differently depending on the genetic background. Some proliferated abnormally, others died early.
And when you fixed the genes in the deletion?
Each gene we restored affected a completely different set of downstream genes, depending on which family the cells came from. It's not a two-hit problem. It's many hits, all across the genome, in different combinations.
Does this mean a healthy parent could pass on risk without knowing it?
Yes. We found that even healthy donors carried genetic variants that could contribute to neurodevelopmental problems if combined with the deletion. They're fine on their own, but in the right context—or wrong context—they matter.
What does this mean for treatment?
It means we can't treat everyone with this deletion the same way. A therapy that works for one family might not work for another. You need to understand each person's genetic architecture.